Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with rectal cancer (a type of cancer starting in the rectum) confirmed by a laboratory tissue test
- People whose cancer showed a complete response — meaning no signs of cancer were found after initial treatment given before surgery (called neoadjuvant therapy)
- People who have given their informed consent to take part in a study focused on preserving the organ (the rectum) rather than removing it
Who may not be able to join:
- People whose cancer has spread to other parts of the body (known as metastatic disease)
- People who did not receive any treatment before surgery (neoadjuvant therapy) as part of their care
- People who are unable to understand the information explaining the possible risks and benefits of joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Toni T Seppälä, MD, PhD, Tampere University Hospital
Phone: +358444722846
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Disease-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.